Company Overview - Sagimet is a clinical stage biopharmaceutical company focused on developing programs that inhibit fatty acid synthase (FASN) [2] - FASN is an enzyme that regulates various organs and pathways in the body, and its overexpression is linked to several health issues [2] Key Development Areas - The primary development focus is on MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), acne, and certain solid tumors in oncology that require FASN for disease progression [2] - Significant work has been conducted in MASH and acne, with preclinical and clinical studies demonstrating the effectiveness of the lead molecule, denifanstat [3]

Summary of Sagimet Biosciences (SGMT) Conference Call Company Overview - Sagimet Biosciences is a clinical stage biopharmaceutical company focused on developing programs that inhibit fatty acid synthase (FASN) [5][6] - The company is primarily targeting indications such as Non-Alcoholic Steatohepatitis (NASH), acne, and certain solid tumors in oncology [5][6] Key Priorities and Developments - The lead molecule, danifanstat, has shown effectiveness in normalizing FASN levels, leading to improved outcomes in NASH by reducing fat, inflammation, and fibrosis [6][7] - Upcoming catalysts include: - A Phase I pharmacokinetic study in combination with resmineram for NASH patients, expected to start soon with data anticipated by the end of 2025 [7][8] - A Phase I study for the next-generation molecule 3,567 in acne, with completion expected by early 2026 and a Phase II program to follow [8] Mechanism of Action - FASN is crucial in converting sugars to fats, and its inhibition leads to reduced fatty acid production, impacting both liver health in NASH and inflammation in acne [10][11] - The mechanism for acne involves inhibiting the production of sapienic acid, which is linked to pimple formation [12][13] Clinical Trial Insights - The Phase III trial conducted by partner Ascletis in China for acne showed statistically significant results across all primary and secondary endpoints, with a favorable safety profile [16][17] - The acne market has not seen significant innovation in over 40 years, with the last major product being Accutane, which peaked at approximately $1 billion in sales in 2008 [32][33] Market Opportunity - The U.S. acne market presents a significant opportunity, with about 50 million Americans affected, and 10-15 million suffering from moderate to severe acne [30] - Only 5.1% of those with acne are actively treated by dermatologists, indicating a large potential for market penetration [30] Safety and Tolerability - The drug was well tolerated in trials, with fewer instances of dry eye compared to placebo, and minimal reports of hair thinning [22][23] - The company believes previous safety concerns in NASH trials were outliers due to external factors like COVID-19 [24][25] Regulatory Environment - The FDA has shown openness to non-invasive study proposals for NASH, which could lower costs and expedite enrollment [40][41] - Sagimet has breakthrough designation, allowing for more direct communication with the FDA regarding study designs [44] Financial Position - The company reported approximately $135 million in cash, expected to fund operations until 2028, covering ongoing trials and development of the next-generation acne molecule [58] Future Directions - Sagimet is exploring additional dermatological indications for FASN inhibition beyond acne [39] - The combination therapy approach is seen as a future direction for treating NASH, with expectations of synergistic effects from combining danifanstat with resmineram [56][57]

My thesis for Sagimet Biosciences Inc. (NASDAQ: SGMT ) is pretty straightforward: this is a small-cap biotech with a very novel mechanism. Blocking fatty acid synthase could give it a real edge in the MASH market. Denifanstat hasI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an app ...

SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences. Cantor Global Healthcare Conference in New York on September 3, 2025, with a fireside chat at 1:35 p.m. ET / 10:35 a.m. PT; andH.C. Wainwright 27th Annual Global Investment Conference in New York on Se ...

Group 1 - Sagimet Biosciences Inc. (SGMT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][4][6] - The Zacks rating system focuses on a company's earnings picture, tracking the Zacks Consensus Estimate for EPS from sell-side analysts, which reflects the company's future earnings potential [2][5] - The recent increase in earnings estimates for Sagimet Biosciences suggests an improvement in its underlying business, likely leading to increased stock price due to investor interest [6][9] Group 2 - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [8][10] - Sagimet Biosciences is expected to earn -$1.85 per share for the fiscal year ending December 2025, with a 25.6% increase in the Zacks Consensus Estimate over the past three months [9][11] - The upgrade to Zacks Rank 2 places Sagimet in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10][11]

Group 1 - Sagimet Biosciences Inc. (SGMT) has experienced a significant decline of 28% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for SGMT is currently at 29.42, suggesting that the heavy selling pressure may be exhausting itself [5] - There is a strong consensus among Wall Street analysts that SGMT will report better earnings than previously predicted, with a 13.2% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - SGMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a potential turnaround [8]

Exhibit 99.2 Targeting Metabolic Dysfunction with Novel Therapies to Treat M ASH, Acne & Cancer August 2025 Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provi Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statement conditions, including but not limited to, statements regarding possible or assumed future results of operations, busines pla ...

Table of Contents Sagimet Biosciences Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41742 (Exact name of registrant as specified in its charter) (State or other jurisdic ...

Core Insights - Sagimet Biosciences has made significant progress in developing therapeutics for metabolic dysfunction associated steatohepatitis (MASH) and acne, with denifanstat meeting all primary and secondary endpoints in a Phase 3 clinical trial in China [2][5] - The company has initiated a Phase 1 clinical trial for TVB-3567, a new FASN inhibitor for acne treatment in the U.S., and plans to evaluate a combination of denifanstat and resmetirom in a Phase 1 trial in late 2025 [2][11] Recent Corporate Highlights - Denifanstat's Phase 3 trial in China involved 480 patients and demonstrated a treatment success rate of 33.2% compared to 14.6% for placebo, with significant reductions in total lesion count and inflammatory lesions [5] - The Phase 1 trial for TVB-3567 is designed to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants, including those with acne [4][11] Financial Results - As of June 30, 2025, the company reported cash and cash equivalents of $135.5 million, with research and development expenses of $7.2 million for the quarter, up from $6.3 million in the same period in 2024 [11][12] - The net loss for the three months ended June 30, 2025, was $10.4 million, compared to $8.1 million for the same period in 2024 [11][12] Industry Context - Acne affects over 50 million people annually in the U.S., and there has been limited innovation in treatment options over the past 40 years, highlighting the potential market opportunity for new therapies like denifanstat [4][14] - MASH is a progressive liver disease impacting over 115 million people globally, with only one recently approved treatment in the U.S., indicating a significant unmet medical need [13]

Investor Contact: SAN MATEO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a fireside chat at the Canaccord Genuity 45 Annual Growth Conference on Wednesday, August 13, 2025, at 2 p.m. EDT in Boston, MA. A webcast of the fireside chat will be available in the Investors & Media section of Sagi ...